Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II randomized control trial assesses the effect of Urolithin A (Uro-A) supplementation compared to placebo in men with biopsy-confirmed prostate cancer undergoing radical prostatectomy (RP) progressive disease. A total of 90 men will be accrued and randomized 1:1 to receive a 1000 mg daily dose of Uro-A in two 250 mg capsules PO BID or two placebo capsules BID daily for 3 to 6 weeks prior to RP. The primary endpoint is to determine the effect of Uro-A on decreasing prostate tumor tissue oxidative stress (measured by 8-OHdG) compared to placebo.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rak gruczołu krokowego (adenocarcinoma) na podstawie biopsji
- •Wiek 18 lat i więcej
- •Planowana operacja usunięcia prostaty w ciągu 3-6 tygodni
- •Zainfekowani wirusem HIV na skutecznej terapii z niezauważalnym wirusem
- •Zainfekowani wirusem zapalenia wątroby B lub C - tylko jeśli wirus jest nieaktywny
- •Zdolność do zrozumienia badania i podpisania zgody
✗ Disqualifies
- •Wcześniejsze leczenie raka prostaty lub hormonalne
- •Aktywne uzależnienie od alkoholu lub narkotyków
- •Już przyjmowanie Urolityny A lub suplementów z granatu
- •Uczestnictwo w innych badaniach eksperymentalnych
- •Alergia na związki podobne do Urolityny A
- •Choroby psychiatryczne lub sytuacje uniemożliwiające udział w badaniu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 25, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (5)
Cedars-Sinai Medical Center
Los Angeles, United States
Northwestern University
Chicago, United States
University of Chicago Comprehensive Cancer Center
Chicago, United States
Duke University Medical Center
Durham, United States
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, United States
Trial contact
Stephen J. Freedland
Stephen J. Freedland
PRINCIPAL_INVESTIGATOR
Ashley E. Ross
Ashley E. Ross
PRINCIPAL_INVESTIGATOR
Abhinav Sidana
Abhinav Sidana
PRINCIPAL_INVESTIGATOR
Judd W. Moul
Judd W. Moul
PRINCIPAL_INVESTIGATOR
David F. Jarrard
David F. Jarrard
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/26/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.